Infectious Diseases Pharmacy Specialty Review Course for Recertification, Workbook Chapters + RECERT Assessment Package (L269091)

ACPE #: 0204-9999-26-925-H01-P 

Antimicrobial Stewardship  

• Outline components of an effective stewardship program. 
• Select appropriate resources; relevant accreditation, legal, regulatory, and safety requirements; and quality metrics related to infectious diseases. 
• Evaluate institutional treatment policies and pathways for compliance with antimicrobial stewardship guidelines, surveillance data, and best available evidence. 
• Assess the effectiveness of infection prevention strategies. 
• Identify metrics for evaluating the value of infectious diseases pharmacy services. 

Upper Respiratory Tract Infections  

• Assess pharmacotherapies for upper respiratory tract infections.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence. 
• Recommend modifications of patient-specific treatment plans based on efficacy and adverse effects. 
• Identify recommended immunizations and potential adverse effects. 

Lower Respiratory Tract Infections  

• Assess pharmacotherapies for lower respiratory tract infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics. 
• Assess the advantages and disadvantages of pharmacotherapies for viral pneumonia, including recommendations for specific patient populations. 
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence. 
• List recommended immunizations and screening guidelines for patients with or at risk for COVID-19, influenza, and respiratory syncytial virus.  
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results. 
• Recommend the most appropriate modifications of patient-specific treatment plans based on efficacy, adverse effects, and follow-up assessment. 
• Interpret biomedical literature with regard to study design and methodology, significance of reported data and conclusions, limitations, and applicability of study results to patients with lower respiratory tract infections.  

ACPE #: 0204-9999-26-926-H01-P  

HIV Infection and AIDS  

• Assess pharmacotherapies for HIV‐infection and AIDS, including opportunistic infections. 
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence. 
• List recommended immunizations and screening guidelines for patients with HIV. 
• Recommend modifications of patient‐specific treatment plans based on efficacy, drug interactions, immunologic or virologic response, and adverse effects. 
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results related to HIV infection. 
• Evaluate a plan to facilitate transitions of care. 

Infections of Reproductive Organs and Sexually Transmitted Infections  

• Assess pharmacotherapies for infections of reproductive organs and sexually transmitted diseases. 
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence. 
• Identify recommended screening guidelines for sexually‐transmitted diseases. 
• Recommend modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects. 
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results. 
• Summarize key considerations in effective patient and caregiver education and counseling techniques. 

Opportunistic Infections in Immunocompromised Patients  

• Assess the advantages and disadvantages of pharmacotherapies for opportunistic infections in immunocompromised patients, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics. 
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information and best available evidence.
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results. 
• Recommend modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects.
• Identify preventative therapies in immunocompromised patients. 

ACPE #: 0204-9999-26-927-H01-P  

Fungal Infections  

• Assess pharmacotherapies for invasive fungal infections including aspergillosis, candidiasis, dimorphic fungi, and cryptococcosis. 
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information and best available evidence. 
• Recommend modifications of patient-specific treatment plans based on efficacy, immunologic response, and adverse effects. 
• Identify potential adverse effects and drug-drug interactions. 

Statistics, Evidence-based Medicine, and Research Design 

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with melanoma or non-melanoma skin cancer. 
• Discuss short- and long-term goals, including post-therapy and survivorship, with a patient with melanoma or non-melanoma skin cancer and his or her caregiver. 
• Select relevant information and guidance for the public regarding melanoma and non-melanoma skin cancer-related issues (e.g., risk factors, prevention, screening).  
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of melanoma and non-melanoma skin cancers, including thyroid level monitoring for chemotherapy agents, immune-mediated toxicities, and toxicity from BRAF inhibitors.  

ACPE #: 0204-9999-26-929-H01-P 

Bone and Joint Infections and Skin and Soft Tissue Infections   

• Assess the advantages and disadvantages of pharmacotherapies for bone and joint infections and skin and soft tissue infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics. 
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence. 
• Identify drug‐related problems associated with the therapeutic plan. 
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results. 
• Recommend modifications of patient‐specific pharmacotherapeutic plans based on efficacy and adverse effects. 
• Describe the etiology, diagnosis, and treatment of acute bacterial osteomyelitis and septic arthritis in pediatric patients.  

Central Nervous System Infections  

• Assess pharmacotherapies for central nervous system infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics. 
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence. 
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results. 
• Identify preventive therapies for central nervous system infections. 

Clinical Microbiology  

• Explain the mechanisms of antimicrobial resistance among various pathogens. 
• Identify basic microbiology laboratory procedures. 
• Interpret laboratory and other diagnostic test results relevant to the diagnosis, management, and monitoring of patients with infectious diseases. 
• Evaluate biomedical literature with regard to study design and methodology specific to infectious diseases. 

ACPE #: 0204-9999-26-930-H01-P  

 Gastrointestinal and Intra-abdominal Infections

• Assess pharmacotherapies for gastrointestinal and intra‐abdominal infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics. 
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence. 
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results. 
• Recommend modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects.